Intervet/Schering-Plough Animal Health reintroducing Vista® vaccine line to U.S.market

Summit NJ, Jan. 21, 2011 – Intervet/Schering-Plough Animal Health is reintroducing to the United States market the Vista® vaccine line, which provides dairy veterinarians and producers with the most complete protection available against the most common and costly bovine respiratory and reproductive diseases.

Vista vaccines protect dairy cattle against Infectious Bovine Rhinotracheitis (IBR), Bovine Viral Diarrhea (BVD Type 1 and Type 2), Parainfluenza3 (PI3), Bovine Respiratory Syncytial Virus (BRSV), leptospirosis, vibriosis, Mannheimia haemolytica and Pasteurella multocida.

The Vista line of vaccines was introduced to the market in 2005 with more research supporting its safety and efficacy than any other cattle vaccine at the time. A stop sale was issued on the vaccine in 2009 due to a variability issue with the BRSV antigen. Intervet/Schering-Plough Animal Health worked with the U.S. Department of Agriculture to resolve the issue and is pleased to welcome back this cattle vaccine to its portfolio and the market with even more research that confirms its superior respiratory and reproductive disease protection.

“Intervet/Schering-Plough Animal Health is committed to providing innovative, high-quality animal-health products that dairy veterinarians and producers trust,” says Ron Bryant, who leads the U.S. non-confined beef and dairy cattle business for Intervet/Schering-Plough Animal Health. “We are excited to welcome back Vista to our portfolio of products, are committed to being a reliable supplier and are confident Vista will deliver the protection needed to keep dairy animals healthy and productive.”

Respiratory protection

Vista provides the most complete protection from bovine respiratory disease (BRD), commonly known as pneumonia, which is the most prevalent disease in calves older than 30 days. Long-term effects of pneumonia include a negative impact on growth, reproductive performance, milk production and longevity.

Vista provides the following respiratory health benefits:

  • The only avirulent-live culture Mannheimia haemolytica/Pasteurella multocida protection combined with a five-way modified-live viral (MLV)
  • At least 182-day duration of immunity (DOI) for IBR and 206- and 200-day DOI for BVD Type 1 and Type 2, respectively
  • BRSV protection in a single-dose
  • Proven cell-mediated immunity (CMI) response to IBR, BVD Type 1 and Type 2 and BRSV viruses

Avirulent-live advantages

Vista Once SQ is the only avirulent-live culture Mannheimia haemolytica/Pasteurella multocida protection combined with a MLV five-way viral. Mannheimia haemolytica and Pasteurella multocida are common causes of BRD, and Vista’s unique avirulent-live technology helps lead to a more complete immune response.

“Vista’s avirulent-live M. haemolytica and P. multocida fractions provide an immune response that more closely simulates that occurring in natural infection,” says Scott Nordstrom, D.V.M., director of Dairy Technical Services for Intervet/Schering-Plough Animal Health. “This provides a more comprehensive level of immunity compared to killed vaccines. In addition, its non-adjuvanted formulation reduces reactions and minimizes tissue damage.”

Reproductive protection

Vista provides the most complete protection from reproductive diseases in cattle, including IBR, BVD Type 1, BVD Type 2, leptospirosis and vibriosis. Reproductive diseases reduce conception rates, cause abortion and reduce calving percentages.

Vista provides the following reproductive health benefits:

  • At least 217-day DOI for IBR and 206-day DOI for BVD Type 1 and Type 2
  • Persistent and fetal (congenital) infection protection for BVD Type 1 and Type 2
  • Protection against Leptospira hardjo, including L. borgpetersenii serovar hardjo-bovis – available in a five-way viral / five-way Lepto combination
  • IBR abortion protection
  • Prevention of L. hardjo-bovis urinary shedding
  • Single-dose L. hardjo-bovis protection
  • Campylobacter fetus protection

Complete fetal protection

Vista is the only vaccine labeled for BVD Type 1 and Type 2 protection throughout the entire pregnancy, offering complete fetal protection. Vista provides protection for both persistent infection, for less than 120 days of gestation, and for fetal (or congenital) infection, after 120 days of gestation.

“It’s important to protect the fetus during the entire pregnancy and not just the first 120 days,” Nordstrom says. “Research1 has demonstrated that if a cow contracts an acute BVD infection after 120 days of pregnancy, the virus still can infect the unborn calf and have devastating effects.”

“Infected animals may not live through the pregnancy, may be born with congenital abnormalities or be born looking perfectly normal,” Nordstrom says. “However, these calves can get acutely sick more than twice as often as unaffected calves, and heifers can be delayed in getting pregnant.”

No impact on milk production

For dairy producers, the impact their management practices may have on milk production is a key consideration, and their vaccination programs are no exception. Intervet/Schering-Plough Animal Health has conducted numerous studies to evaluate vaccination effects on milk production, and its products consistently compare to saline. In comparing Vista 5 L5 SQ to saline2, there has been no statistically significant difference in milk production.

“Dairy producers can be confident that their dairy cows won’t drop in milk production when using Vista,” Nordstrom says. “Vista is manufactured using technology that minimizes the amount of endotoxin in the vaccine, which limits negative side effects from vaccination.”

Presentations

Vista vaccines are available in the following presentations:

Vista Once SQ: 10 and 50-dose; avirulent-live culture for M. haemolytica and P. multocida; MLV

for IBR, BVD Type 1 and Type 2, PI3 and BRSV

Vista 5 SQ: 10 and 50-dose; MLV for IBR, BVD Type 1 and Type 2, PI3 and BRSV
Vista 5 L5 SQ: 5, 10 and 50-dose; MLV for IBR, BVD Type 1 and Type 2, PI3 and BRSV; Leptospira: L. canicola, L. grippotyphosa, L. hardjo (including the L. borgpetersenii serovar hardjo-bovis), L. icterohaemorrhagiae and L. pomona
Vista 5 VL5 SQ: 10 and 50-dose; MLV for IBR, BVD Type 1 and Type 2, PI3 and BRSV; Leptospira: L. canicola, L. grippotyphosa, L. hardjo (including the L. borgpetersenii serovar hardjo-bovis), L. icterohaemorrhagiae, L. pomona; and Campylobacter fetus
Vista 3 SQ: 50-dose; MLV for IBR, BVD Type 1 and Type 2
Vista 3 VL5 SQ: 10 and 50-dose; MLV for IBR, BVD Type 1 and Type 2; Leptospira:

L. canicola, L. grippotyphosa, L. hardjo (including the L. borgpetersenii serovar hardjo-bovis), L. icterohaemorrhagiae, L. pomona; and Campylobacter fetus

Vista vaccines are available through veterinarians and animal-health suppliers. Producers are encouraged to work with their veterinarians to design a vaccination-management program appropriate for their herds.

For more information about Vista, or to learn more about Intervet/Schering-Plough Animal Health’s full line of innovative, high-quality cattle health products, call customer service at 1-800-521-5767 or visit www.intervet.com.

1 American Journal of Veterinary Research, Vol. 64, No. 3

2 Intervet/Schering-Plough Animal Health Technical Bulletin

background_banner